We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Places Clinical Hold on Second Idenix Hepatitis Drug
FDA Places Clinical Hold on Second Idenix Hepatitis Drug
August 31, 2012
The FDA has placed a “precautionary” clinical hold on Idenix Pharmaceuticals’ next-generation nucleotide polymerase inhibitor, IDX19368, being developed to treat hepatitis C (HCV) infection.